Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis

Journal of Thrombosis and Thrombolysis

Volumn 19, Issue 3, 2005, Pages 173-181

  Chong, Beng H ^a,b,c   Brighton, Tim A ^c   Baker, Ross I ^d   Thurlow, Peter ^e   Lee, Choon H ^f   Salem, H ^g   Gallo, J ^h   Clowes, C ⁱ   Hertzberg, M ^j   Heaton, D ^k   Leahy, M ^l   Gibbs, H ^m   Ziaja, K ⁿ   Karrim, A ^o   Louwrens, H ^p   Wright, N ^q   Barry, R ^r   Jeffrey, P ^s   Kadwa, A ^t   Szoztek, M ^u   Michalak, J ^v   Bester, F C J ^w   more..

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e AUSTIN HEALTH   (Australia)

^f NEPEAN HOSPITAL   (Australia)

^g BOX HILL HOSPITAL   (Australia)

^h LIVERPOOL HOSPITAL   (Australia)

ⁱ BANKSTOWN LIDCOMBE HOSPITAL   (Australia)

^j WESTMEAD HOSPITAL   (Australia)

^k CHRISTCHURCH HOSPITAL   (New Zealand)

^l FREMANTLE HOSPITAL   (Australia)

^m PRINCESS ALEXANDRA HOSPITAL   (Australia)

ⁿ 1St Dept Clin Gen and Vasc Surg   (Poland)

^o HELEN JOSEPH HOSPITAL   (South Africa)

^p N1 City Hospital   (South Africa)

^q Sunninghill Hospital   (South Africa)

^r Universitas Private Hospital   (South Africa)

^s Vincent Palotti Hospital   (South Africa)

^t Chelmford Medical Centre No2   (South Africa)

^u Clinic of Surgery and Thoracic Diseases   (Poland)

^v Clinic of Angiosurgery   (Poland)

^w Fichmed Medical Centre   (South Africa)

more..

Author keywords

Deep vein thrombosis; Enoxaparin; Home treatment; Unfractionated heparin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ENOXAPARIN; HEPARIN;

ABDOMINAL BLEEDING; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ANEMIA; ARTICLE; BLEEDING; BOLUS INJECTION; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEMATURIA; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL PATIENT; HUMAN; INCIDENCE; INJECTION SITE REACTION; INSOMNIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTPATIENT; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SIDE EFFECT; SKIN BRUISING;

ADULT; AGED; AMBULATORY CARE; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FEMALE; HEMORRHAGE; HEPARIN; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PULMONARY EMBOLISM; VENOUS THROMBOSIS;

EID: 23844446065     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-005-1848-x     Document Type: Article

References (30)

1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med 1998;158:585-593. 10.1001/archinte.158.6.585
2. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992;232:155-160. 1506812
3. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-938. 10.1001/archinte.151.5.933
4. Hirsh J. Heparin. N Engl J Med 1991;324:1565-1574. 2027360
5. Hirsh J, Van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WL. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976;53:691-695. 1253392
6. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993;153:1541-1546. 10.1001/ archinte.153.13.1541
7. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-982. 1545850
8. Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994;72:186-190. 7831649
9. Fiessinger JN, Lopez-Fernandez M, Gatterer E, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996;76:195-199. 8865530
10. The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997;337:657-662.
11. Merli G, Spiro TE, Olsson CG, et al., for the Enoxaparin Clinical Trial Group. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001;134:191-202.
12. Leizorovicz A, Simonneau G, Decousus H, Boissel JP. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis. Br Med J 1994;309:299-304.
13. Lensing AW, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 1995;155:601-607. 10.1001/archinte.155.6.601
14. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. Am J Med 1996;100:269-277. 10.1016/S0002-9343(97)89484-3
15. Walenga JM, Hoppensteadt D, Fareed J. Laboratory monitoring of the clinical effects of low molecular weight heparin. Thromb Res 1991;14(Suppl):49-62. 10.1016/0049-3848(91)90403-J
16. Salzman EW. Low molecular weight heparin: Is small beautiful? N Engl J Med 1986;315:957-959.
17. A randomised trial of subcutaneous low molecular weight heparin (CY 216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A collaborative European multicentre study. Thromb Haemost 1991;65:251-256.
18. Prandoni P, Lensing AW, Buller HR, et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-445. 10.1016/ 0140-6736(92)91054-C
19. Van den Belt AG, Bossuyt PM, Prins MH, Gallus AS, Buller HR. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis - an economic evaluation. TASMAN Study Group. Thromb Haemost 1998;79:259-263. 9493572
20. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999;130:789-799. 10366368
21. Belcaro G, Nicolaides AN, Cesarone MR, et al. Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis. Angiology 1999;50:781-787. 10535716
22. Lindmarker P, Holmstrom M. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Thrombosis Dalteparin Trial Group. J Intern Med 1996;240:395-401. 10.1046/j.1365-2796.1996.81877000.x
23. Goldhaber SZ, Tapson VF; DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004;93:259-262. 14715365
24. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334:677-681. 10.1056/NEJM199603143341101
25. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996;334:682-687. 10.1056/NEJM199603143341102
26. Lopaciuk S, Meissner AJ, Filipecki S, et al. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: A Polish multicenter trial. Thromb Haemost 1992;68:14-18. 1325076
27. Boccalon H, Elias A, Chale JJ, Cadène A, Gabriel S. Clinical outcome and cost of hospital vs. home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: The Vascular Midi-Pyrenees study. Arch Intern Med 2000;160:1769-1773. 10.1001/ archinte.160.12.1769
28. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997;157:2562-2568. 10.1001/ archinte.157.22.2562
29. Hylek EM, Regan S, Henault LE, et al. Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis. Arch Intern Med 2003;163:621-627. 10.1001/archinte.163.5.621
30. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:324-327. 5041701